Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantation.

Haas PS, Ihorst G, Schnitzler S, Wäsch R, Marks R, Bertz H, Mertelsmann R, Finke J, Deschler B.

Ann Hematol. 2012 Dec;91(12):1929-35. doi: 10.1007/s00277-012-1529-8. Epub 2012 Jul 31.

PMID:
22847152
2.

[Prevention of infections and thromboses after splenectomy or because of functional loss of the spleen].

Engelhardt M, Haas PS, Theilacker C, Eber SW, Schmugge M, Kern WV, Heimpel H.

Dtsch Med Wochenschr. 2009 Apr;134(17):897-902. doi: 10.1055/s-0029-1220231. Epub 2009 Mar 31. Review. German.

PMID:
19337961
3.

The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS).

Haas PS, Roy NB, Gibbons RJ, Deville MA, Fisher C, Schwabe M, Bissé E, van Dorsselaer A, Higgs DR, Lübbert M.

Br J Haematol. 2009 Feb;144(4):538-45. doi: 10.1111/j.1365-2141.2008.07505.x.

PMID:
19055664
4.

Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses.

Haas PS, Denz U, Ihorst G, Engelhardt M.

Eur J Haematol. 2008 Apr;80(4):303-9. doi: 10.1111/j.1600-0609.2007.01022.x. Epub 2007 Dec 21.

PMID:
18182082
5.

State of the art therapy in multiple myeloma and future perspectives.

Denz U, Haas PS, Wäsch R, Einsele H, Engelhardt M.

Eur J Cancer. 2006 Jul;42(11):1591-600. Epub 2006 Jul 3. Review.

PMID:
16815703
6.
7.

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.

Haas PS, Bauchmüller K, Kühnemund A, Finke J, Ihorst G, Engelhardt M.

Ann Hematol. 2006 Mar;85(3):191-3. Epub 2005 Dec 20. No abstract available.

PMID:
16365747
8.

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.

Pitako JA, Haas PS, Van den Bosch J, Müller-Berndorff H, Kündgen A, Germing U, Wijermans PW, Lübbert M.

Ann Hematol. 2005 Dec;84 Suppl 1:25-31.

PMID:
16292666
9.

Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.

Haas PS, Wijermans P, Verhoef G, Lübbert M.

Leuk Res. 2006 Mar;30(3):338-42. Epub 2005 Sep 12.

PMID:
16162357

Supplemental Content

Support Center